ATE161190T1 - Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung - Google Patents

Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung

Info

Publication number
ATE161190T1
ATE161190T1 AT92922246T AT92922246T ATE161190T1 AT E161190 T1 ATE161190 T1 AT E161190T1 AT 92922246 T AT92922246 T AT 92922246T AT 92922246 T AT92922246 T AT 92922246T AT E161190 T1 ATE161190 T1 AT E161190T1
Authority
AT
Austria
Prior art keywords
lfa
inhibitors
interaction
antigen
prevention
Prior art date
Application number
AT92922246T
Other languages
English (en)
Inventor
Barbara P Wallner
Kevin D Cooper
Original Assignee
Biogen Inc
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Univ Michigan filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE161190T1 publication Critical patent/ATE161190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92922246T 1991-10-07 1992-10-06 Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung ATE161190T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77096991A 1991-10-07 1991-10-07
US86202292A 1992-04-02 1992-04-02
HK98105235A HK1006056A1 (en) 1991-10-07 1992-10-06 Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

Publications (1)

Publication Number Publication Date
ATE161190T1 true ATE161190T1 (de) 1998-01-15

Family

ID=27269909

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922246T ATE161190T1 (de) 1991-10-07 1992-10-06 Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung

Country Status (10)

Country Link
EP (1) EP0607332B1 (de)
JP (3) JPH07502496A (de)
AT (1) ATE161190T1 (de)
AU (1) AU677772B2 (de)
CA (1) CA2120732C (de)
DE (1) DE69223638T2 (de)
ES (1) ES2112335T3 (de)
GR (1) GR3026135T3 (de)
HK (1) HK1006056A1 (de)
WO (1) WO1993006866A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502495A (ja) * 1991-10-07 1995-03-16 バイオゲン　インコーポレイテッド 特定種のｌｆａ−３またはｃｄ２結合蛋白質を投与することによる同種移植または異種移植の寛容性を改善するための方法
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
ES2153895T3 (es) 1994-03-08 2001-03-16 Dana Farber Cancer Inst Inc Metodos para modular la insensibilidad de celulas t.
US6185457B1 (en) 1994-05-31 2001-02-06 Galvani, Ltd. Method and apparatus for electrically forcing cardiac output in an arrhythmia patient
WO1999022765A1 (en) * 1997-10-30 1999-05-14 Brigham And Women's Hospital Control of lymphocyte localization by leep-cam activity
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
GEP20063828B (en) * 2001-02-01 2006-05-10 Biogen Inc Methods for Treating or Preventing Skin Disorders Using CD2-Binding Agents
WO2003009740A2 (en) 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
CA2497628A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
BR122015032743B1 (pt) 2004-06-01 2018-04-03 Mount Sinai School Of Medicine Of New York University Vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, seus usos e métodos para produzir uma vacina
US20120052080A1 (en) 2004-09-21 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
EP1855713B1 (de) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Gentechnisch hergestellter pferde-influenza-virus und seine verwendungen
US8483822B1 (en) 2009-07-02 2013-07-09 Galvani, Ltd. Adaptive medium voltage therapy for cardiac arrhythmias
EP2671086B1 (de) 2011-02-03 2018-04-25 Pop Test Oncology LLC System und verfahren für diagnose und behandlung
EP3855184B1 (de) 2012-03-19 2023-12-27 Stemline Therapeutics Inc. Verfahren zur behandlung und überwachung eines karzinomstatus
RS62406B1 (sr) 2012-05-16 2021-10-29 Stemline Therapeutics Inc Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera
US8750990B1 (en) 2012-12-12 2014-06-10 Galvani, Ltd. Coordinated medium voltage therapy for improving effectiveness of defibrillation therapy
KR102232595B1 (ko) 2013-08-30 2021-03-26 피티씨 테라퓨틱스, 인크. 치환된 피리미딘 bmi-1 저해제
EP3261664A1 (de) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalenter schweineinfluenzavirusimpfstoff
EP4300252B1 (de) 2021-02-26 2025-09-10 Panasonic Intellectual Property Management Co., Ltd. Elektronische vorrichtung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503646A1 (de) * 1991-03-12 1992-09-16 Biogen, Inc. Monoklonale Antikörper gegen Lymphozytenfunktionassoziertes Antigen-3
WO1992016622A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Cd2-binding domain of lymphocyte function associated antigen 3
JPH07502495A (ja) * 1991-10-07 1995-03-16 バイオゲン　インコーポレイテッド 特定種のｌｆａ−３またはｃｄ２結合蛋白質を投与することによる同種移植または異種移植の寛容性を改善するための方法

Also Published As

Publication number Publication date
JP2005015493A (ja) 2005-01-20
EP0607332B1 (de) 1997-12-17
AU2890892A (en) 1993-05-03
DE69223638D1 (de) 1998-01-29
DE69223638T2 (de) 1998-05-20
WO1993006866A3 (en) 1993-08-05
GR3026135T3 (en) 1998-05-29
WO1993006866A2 (en) 1993-04-15
ES2112335T3 (es) 1998-04-01
JP2003137810A (ja) 2003-05-14
EP0607332A1 (de) 1994-07-27
CA2120732C (en) 2008-09-16
JPH07502496A (ja) 1995-03-16
CA2120732A1 (en) 1993-04-15
HK1006056A1 (en) 1999-02-05
AU677772B2 (en) 1997-05-08

Similar Documents

Publication Publication Date Title
DE69223638D1 (de) Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
Gélis et al. Assessment of the skin photoprotective capacities of an organo‐mineral broad‐spectrum sunblock on two ex vivo skin models
DE69532042D1 (de) Vorrichtung für elektrophysiologische behandlungen des herzens
ATE132762T1 (de) Vorrichtung zur behandlung von entzündlichen, sich im anfangsstadium befindlichen hautveränderungen
ES8705845A1 (es) Procedimiento de preparar derivados benzonaftalenicos de utilidad terapeutica y cosmetica
ATE530179T1 (de) Verwendung von kreatin und/oder kreatinderivaten in dermatologischen zubereitungen
AT384169B (de) Vorrichtung zum behandeln von lebenden geweben und/oder zellen
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
EA200400951A1 (ru) Способ и процесс создания моложавой, гладкой кожи с малым количеством пор
DE69719495D1 (de) Verwendung von inhibitoren der retinosäureaktivität zur behandlung empfindlicher haut und/oder durch uv strahlung bewirkter akuter schädigungen
PT1028738E (pt) Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
ES2064119T3 (es) Nuevos derivados de aminobenzosultam como inhibidores de la lipoxigenasa.
DE59907195D1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
DE59002154D1 (de) Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid oder ethambutol als aktive wirkstoffe.
DE69717495D1 (de) Verwendung eines terminalia catappa extraktes
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
EP2210956A3 (de) Verfahren zur Hemmung von Zellwachstum mit Oligonukleotiden
DE69628153D1 (de) Verwendung von natriumchlorid zur behandlung der akne und/oder der rosacea
DE602005016198D1 (de) Verwendung von Hülsenfrüchten zur Herstellung von Produkten zum Schutz oder Behandlung von radiotherapie-bedingten Hautschäden
ES2160102T3 (es) Tratamiento del eritema provocado por uv.
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
NO943727D0 (no) Nye cardiobeskyttende midler